4OT6 | Crystal structure of BTK kinase domain complexed with 4-Methanesulfonyl-N-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-benzamide | date | |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
authors | Kuglstatter, A., Wong, A. | ||||||||||||||
compound | source | ||||||||||||||
symmetry |
| ||||||||||||||
crystal cell |
| ||||||||||||||
method | X-Ray Diffraction | resolution | 2.05 | ||||||||||||
ligand | 2V1 | enzyme |
| ||||||||||||
Gene Ontology |
| ||||||||||||||
Primary reference | Structure-Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis., Lou Y, Han X, Kuglstatter A, Kondru RK, Sweeney ZK, Soth M, McIntosh J, Litman R, Suh J, Kocer B, Davis D, Park J, Frauchiger S, Dewdney N, Zecic H, Taygerly JP, Sarma K, Hong J, Hill RJ, Gabriel T, Goldstein DM, Owens TD, J Med Chem. 2014 Apr 16. PMID:24712864 |
Data retrieval |
View 4OT6 in 3D |
Visual 3D analysis of 4OT6 |
Structure-derived information |
Sequence-derived information |
Other resources with information on 4OT6 |
OCA© by Jaime Prilusky, 1996-2014,2022 Bioinformatics Unit Weizmann Institute of Science |